Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Rating of “Hold” from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received a consensus rating of “Hold” from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $380.56.

A number of analysts have weighed in on the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird raised their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday, November 25th. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $420.00 to $350.00 in a report on Friday, September 27th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, TD Cowen decreased their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd.

Institutional Trading of Medpace

Hedge funds have recently bought and sold shares of the stock. Stone House Investment Management LLC bought a new position in shares of Medpace in the 3rd quarter worth $33,000. Ashton Thomas Securities LLC purchased a new stake in shares of Medpace during the third quarter valued at about $37,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Medpace in the 2nd quarter valued at about $52,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the 3rd quarter worth approximately $46,000. Finally, True Wealth Design LLC raised its stake in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.0 %

Medpace stock opened at $350.87 on Friday. Medpace has a 12-month low of $277.72 and a 12-month high of $459.77. The firm has a 50-day moving average price of $341.09 and a 200-day moving average price of $359.82. The firm has a market capitalization of $10.91 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter in the previous year, the business earned $2.22 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, sell-side analysts predict that Medpace will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.